Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. develops and markets small‑molecule oncology & hematology drugs. Tavalisse for immune thrombocytopenia, Rezlidhia for IDH1‑mutant AML, GAVRETO for RET‑positive NSCLC. Active pipeline and strategic partnerships.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 162
HQ: South San Francisco

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
RIGL	Rigel Pharmaceuticals Cap: 0.8B \| P/E: 6.7	EQUITY	NMS	USD	US7665596034	Active	📈